Personalized oncology is revolutionizing patient care. In a SelectScience® webinar, Dr. Christian Regenbrecht, Founder and CEO, Cellular Phenomics & Oncology (CPO), will discuss how comprehensive patient-derived 3D cell culture models can be integrated into the pre-clinical development of novel anti-cancer compounds.
Registration is now open for the event which will explore the benefits of using these cell cultures instead of adherent 2D cell as well as current limitations. Regenbrecht will present a prototypic workflow and explain a semi-automated set-up for high-throughput screening (HTS) and several case studies that demonstrate how patient-derived cell culture models can be used in personalized oncology. You'll also have the chance to ask any questions you may have during the Q&A session.
Who should attend?
Scientists from pharma, biotech and academia who work in the field of pre-clinical drug development. Decision makers who want to explore opportunities to reduce the use of animal models. Oncologists who want to be informed about how this will transform future patient care.